MedTrace Logo

Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon

NCT01328184 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-06-18

Study results available
· View outcomes & findings →

Summary

The objective of this study is to investigate the possible effect of multiple oral doses of 25 mg BI 10773 on the steady state pharmacokinetics of ethinylestradiol (EE) and levonogestrel (LNG) (Microgynon®).

Conditions

  • Healthy

Interventions

DRUG

levonorgestrel

multiple doses

DRUG

levonorgestrel

multiple doses

DRUG

Ethinylestradiol

multiple doses

DRUG

Microgynon + BI 10773

multiple doses BI 10773

DRUG

Ethinylestradiol

multiple doses

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01328184 on ClinicalTrials.gov